Yarrow Bioscience (YARW) Return on Capital Employed (2018 - 2026)
Yarrow Bioscience's (YARW) quarterly Return on Capital Employed came in at 124.44% in Q1 2026, down 3238.0% YoY from 3.97% in Q1 2025, and down 30.67% on a QoQ basis from 95.23% in Q2 2025.
Yarrow Bioscience (YARW) Return on Capital Employed (2018 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Return on Capital Employed data on file, last reported at 124.44% in Q1 2026.
- Quarterly Return on Capital Employed fell 3238.0% year-over-year to 124.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124.44% (down 3238.0% YoY) and the FY2025 annual result came in at 64.48%, up 19.0% from the prior year.
- Return on Capital Employed retreated to 124.44% in Q1 2026, from 95.23% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 35.06% in Q1 2024 to a low of 194.15% in Q3 2023.
- A 5-year average of 92.82% and a median of 93.65% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 13932 bps — and 2025, when it plunged 5700 bps.
- Tracing YARW's Return on Capital Employed over 5 years: stood at 99.44% in 2022, then soared by 42 bps to 57.44% in 2023, then sank by 34 bps to 76.92% in 2024, then retreated by 24 bps to 95.23% in 2025, then tumbled by 31 bps to 124.44% in 2026.
- The last three Return on Capital Employed figures came in at 124.44% (Q1 2026), 95.23% (Q2 2025), and 92.06% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | -101.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -101.99% |
| Mar 31, 2026 | -124.44% |
| Jun 30, 2025 | -95.23% |
| Mar 31, 2025 | -92.06% |
| Dec 31, 2024 | -76.92% |
| Sep 30, 2024 | -54.83% |
| Jun 30, 2024 | -39.84% |
| Mar 31, 2024 | -35.06% |
| Dec 31, 2023 | -57.44% |
| Sep 30, 2023 | -194.15% |
| Jun 30, 2023 | -141.17% |
| Mar 31, 2023 | -103.24% |
| Dec 31, 2022 | -99.44% |
| Dec 31, 2021 | -69.77% |
| Sep 30, 2021 | -60.07% |
| Jun 30, 2021 | -77.16% |
| Mar 31, 2021 | -222.62% |
| Dec 31, 2020 | -319.89% |
| Sep 30, 2020 | -278.95% |
| Jun 30, 2020 | -220.41% |